JAZZJazz Pharmaceuticals plc
$218.41+70% 1Y
$218.41
$127.0052 weeks$261.72
The financials
Jazz Pharmaceuticals plc by the numbers
Jazz Pharmaceuticals plc (JAZZ) reported revenue of $1.21B in Q2 2026 (quarter ended Jun 30, 2026), up 16% from the same quarter a year earlier. That came with net income of $193M (16% of revenue). For the full year FY2025, revenue was $4.27B (+4.9% year on year) and net income −$356M. Its largest product in Q2 2026 was Oncology at $362M, 31% of the disclosed total, ahead of Epilepsy at 25%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $1.21B | $1.05B | +16% |
| Operating income | $248M | −$686M | to a profit |
| Net income | $193M | −$719M | to a profit |
| Diluted EPS | $2.78 | −$11.74 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Oncology | $362M | 31% |
| Epilepsy | $292M | 25% |
| Zepzelca | $106M | 9.2% |
| Rylaze Enrylaze | $100M | 8.6% |
| Defitelio Defibrotide | $62M | 5.4% |
| Product And Services Royalties And Contract | $52M | 4.5% |
| Modeyso | $48M | 4.2% |
| High Sodium AG Oxybate Product Royalty | $42M | 3.7% |
| Vyxeos | $31M | 2.7% |
| Xyrem | $31M | 2.6% |
| Ziihera | $15M | 1.3% |
| Other Royalty And Contract | $10M | 0.9% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $1.15B (+11%)
Modeyso grew +9540% year on yearOther Products -100% year on year
Segment Latestquarter on quarteryear on year
- Oncology$362.3M$362.3Mquarter on quarter +8.7%year on year +32%+8.7%+32%
- Epilepsy$292.1M$292.1Mquarter on quarter +17%year on year +16%+17%+16%
- Zepzelca$105.8M$105.8Mquarter on quarter +4.8%year on year +42%+4.8%+42%
- Rylaze Enrylaze$99.5M$99.5Mquarter on quarter -4.1%year on year -1.2%-4.1%-1.2%
- Defitelio Defibrotide$62.0M$62.0Mquarter on quarter +31%year on year +29%+31%+29%
- Product And Services Royalties And Contract$52.2M$52.2Mquarter on quarter +20%year on year -13%+20%-13%
- Modeyso$48.2M$48.2Mquarter on quarter +16%year on year +9540%+16%+9540%
- High Sodium AG Oxybate Product Royalty$42.2M$42.2Mquarter on quarter +16%year on year -22%+16%-22%
- Vyxeos$31.4M$31.4Mquarter on quarter +18%year on year -30%+18%-30%
- Xyrem$30.5M$30.5Mquarter on quarter -2.2%year on year -14%-2.2%-14%
- Ziihera$15.4M$15.4Mquarter on quarter +16%year on year +157%+16%+157%
- Other Royalty And Contract$10.0M$10.0Mquarter on quarter +37%year on year +67%+37%+67%
- Other Products$0.00$0.00quarter on quarter -100%year on year -100%-100%-100%